A novel study by Canadian physicians reported that the BioSTARTM biodegradable implant achieved comparable closure rates to the Amplatzer Septal OccluderTM (ASO) in children with atrial septal defect ...

A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...

Rochester, MN - A new case series of patients with a previous stroke suggests that transcatheter device closure of patent foramen ovale (PFO) and atrial septal defect (ASD) is safe and eliminated ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio W.L. Gore and Associates announced its ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

SAN DIEGO -- Removal of atrial septal closure devices cleared up persistent symptoms of nickel allergy in a series of 10 consecutive patients reported here. All had systemic symptoms for at least a ...

At 2-year follow-up, a septal occluder device was deemed safe and effective for transcatheter closure of atrial septal defects, according to new data published in Circulation: Cardiovascular ...

Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...

Overall, there was a 15.8% incidence of migraines in the first 3 months following the procedure among people randomized to clopidogrel (Plavix) plus aspirin or aspirin alone. After this initial period ...